Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study Evaluating the Clinical Impact of the Breast Cancer Intrinsic Subtype-Prosigna Test (Assay) in the Management of Early-stage Breast Cancers

NCT02395575 is registered in ClinicalTrials.gov with NanoString Technologies, Inc. as lead sponsor.

NCT NCT02395575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02395575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study Evaluating the Clinical Impact of the Breast Cancer Intrinsic Subtype-Prosigna Test (Assay) in the Management of Early-stage Breast Cancers
Lead sponsor
NanoString Technologies, Inc.
Phase
Observational
Overall status
Completed
Start date
March 31, 2015
Completion date
October 31, 2017
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer